News headlines about Leap Therapeutics (NASDAQ:LPTX) have trended somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Leap Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0811377073061 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Leap Therapeutics (NASDAQ LPTX) traded up $0.14 during trading hours on Tuesday, reaching $6.25. 118,700 shares of the company’s stock were exchanged, compared to its average volume of 23,397. Leap Therapeutics has a 12-month low of $4.90 and a 12-month high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.11). equities analysts forecast that Leap Therapeutics will post -3.15 earnings per share for the current year.

Separately, Zacks Investment Research lowered shares of Leap Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Leap Therapeutics (LPTX) Stock Price” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at

About Leap Therapeutics

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Insider Buying and Selling by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.